According to the Complaint, Edge Therapeutics, Inc. ("Edge" or the "Company") is a clinical-stage biotechnology company that seeks to discover, develop, and commercialize novel, hospital-based therapies capable of transforming treatment paradigms for the management of acute, life-threatening conditions.

This action stems from a proposed transaction announced on November 26, 2018 (the “Proposed Transaction”), pursuant to which Edge will be acquired by PDS Biotechnology Corporation.

On December 21, 2018, Defendants filed a Form S-4 Registration Statement with the United States Securities and Exchange Commission in connection with the Proposed Transaction. The Complaint alleges that the Registration Statement omits material information with respect to the Proposed Transaction, which renders the Registration Statement false and misleading.

This case was voluntarily dismissed on March 12, 2019.